Learn about the latest breakthrough treatment for Post-Partum Depression with LifeStance Executive Medical Director, Specialty Services, Dr. Rachel Dalthorp.
LifeStance Health’s Post
More Relevant Posts
-
Dear Colleagues, What do you do if your patient reports symptoms of a benzodiazepine-induced neurological dysfunction? This video from Alliance medical director, Alexis Ritvo MD MPH, explores the effects of discontinuing benzodiazepine usage and offers strategies to support patients after this process. It starts with findings from a survey on the effects of benzodiazepine use, highlighting the impact and repercussions of withdrawal, as well as the evidence connecting benzodiazepines to an elevated risk of suicide. Finally, the presentation examines alternative approaches to supporting patients with benzodiazepine-induced neurological dysfunction (BIND), including alternative medications, lifestyle adjustments, and coping strategies. https://lnkd.in/gvSGkrVh
Watch Beyond Benzodiazepine Discontinuation: Understanding Life Effects and Support Strategies
psychopharmacologyinstitute.com
To view or add a comment, sign in
-
🍄 PsychedelicInsights.com | The psychological guidance of private psychedelic experiences | Public Speaker | Psychedelic Advocate | Educator | Royal Marine Corps veteran | Opti-Mystic | Multi Dimensional Psilosopher |
[This is why with professional preparation and session guidance higher doses are safer and more positive outcomes] "The authors concluded that the trial showed the feasibility of psilocybin monotherapy for up to 12 weeks in patients with TRD. The change from baseline to week 3 in MADRS total score was significantly better with 25-mg, but not 10-mg, versus the 1-mg dose. Reported adverse effects included headache, nausea, dizziness, and fatigue, as well as numerically higher suicidal ideation and self-injurious behavior in the 25- and 10-mg groups. Psychedelic Insights provides the guidance of #private high dose legal psilocybin truffle experiences for personal transformation. Guided by experienced professionals. For more information, testimonials and our staff or to schedule a call to have all your questions answered, please see: https://lnkd.in/eJgb7Hk" https://lnkd.in/eTiu9z5H
Single-Dose Psilocybin for Treatment-Resistant Major Depression
psychiatrictimes.com
To view or add a comment, sign in
-
Depression is a serious and widespread health problem that affects millions of people worldwide. Many people who struggle with #depression do not find adequate relief from the available treatments. That's why we are actively working to encourage medicine developers to come up with new treatments with 🔸 better efficacy, 🔸 improved safety 🔸 more personalised profiles. 🗓 We have updated our guideline on clinical investigation of antidepressants and we invite developers and researchers to share their feedback on it until 31 March 2024. #Antidepressants #MentalHealth #Medicines Florence Butlen-Ducuing, Marta Kollb-Sielecka, Pavel Balabanov, Marion Haberkamp, George Aislaitner, Bundesinstitut für Arzneimittel und Medizinprodukte, Taina Mattila, Marika Doucet, European Psychiatric Association, , Ewa Bałkowiec-Iskra ( Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Bio)
The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers | European Psychiatry | Cambridge Core
cambridge.org
To view or add a comment, sign in
-
Director Regulatory Labeling Strategy | Safety Label Changes | ex-Novartis | ex-GSK/TCS | ex-Biogen | TLP | CDS | USPI | SmPC | Product Monograph | Label Compliance & Artwork Disclaimer: "All views are my own"
🔉🔉 The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers 🔉🔉 The new European Medicine Guidelines for Antidepressant Drugs are expected to facilitate the development and approval of new and better antidepressants for the treatment of depression, which is one of the most disabling and prevalent mental disorders in the world. It is currently open for public consultation until March 31, 2024. Some of the main aspects of the guidelines: 💊 Guideline introduce a new classification of depressive disorders based on the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), and the International Classification of Diseases, 11th revision (ICD-11), which are more aligned with the current scientific understanding of depression. 💊 Guideline encourages the use of patient-reported outcome measures (PROMs) and digital technologies to capture the multidimensional aspects of depression and its impact on patients' functioning and quality of life. 💊 Guideline acknowledges the need for more personalized and innovative approaches to treat depression, such as pharmacogenomics, biomarkers, combination therapies, and novel mechanisms of action. 💊 Guideline emphasize the importance of assessing the benefit-risk balance of antidepressants in different populations and subgroups, such as children and adolescents, elderly, pregnant and lactating women, and patients with comorbidities or suicidal ideation. #ema #depression #antidepressants #guidelines
Depression is a serious and widespread health problem that affects millions of people worldwide. Many people who struggle with #depression do not find adequate relief from the available treatments. That's why we are actively working to encourage medicine developers to come up with new treatments with 🔸 better efficacy, 🔸 improved safety 🔸 more personalised profiles. 🗓 We have updated our guideline on clinical investigation of antidepressants and we invite developers and researchers to share their feedback on it until 31 March 2024. #Antidepressants #MentalHealth #Medicines Florence Butlen-Ducuing, Marta Kollb-Sielecka, Pavel Balabanov, Marion Haberkamp, George Aislaitner, Bundesinstitut für Arzneimittel und Medizinprodukte, Taina Mattila, Marika Doucet, European Psychiatric Association, , Ewa Bałkowiec-Iskra ( Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Bio)
The new European Medicines Agency guideline on antidepressants: a guide for researchers and drug developers | European Psychiatry | Cambridge Core
cambridge.org
To view or add a comment, sign in
-
BioPharma Practice Leader | Market Access | BD, Licensing & Partnerships | Commercial Strategy | Research & Analysis | Strategic Intelligence |
Postpartum Depression (PPD) – Will the new oral agent boost patient compliance? Ø Postpartum Depression (PPD) is associated with low levels of allopregnanolone, and affects up to 1 million women in the USA annually Ø PPD occurs in women within the first few weeks of giving birth, and as late as 30 weeks postpartum. Most women are treated with psychotherapy and then, as needed, medication. Ø Serotonin reuptake inhibitors (SSRI) are considered first-line for women with PPD without Bipolar Disorder but the data on pharmacotherapy for PPD are limited Ø On Aug 4 2023, Sage/Biogen received approval of ZURZUVAE (zuranolone), the first ever oral medication specifically for the treatment of PPD. We expect meaningful commercial opportunity, given the exclusive label and the benefit of oral administration ------------------------------------------------------------------------------------ Ready to leverage the power of intelligence to drive CNS product development and commercialization strategy? At EOS Intelligence, we offer competitive intelligence monitoring services in key therapeutic areas to make you stay ahead of the curve. Let us know your perspectives & challenges and we will get you covered. Write us at [email protected] #postpartumdepression #postnataldepression #depression #competitiveintelligence #eosintelligence #perspectives #leadership #pharmainnovation #marketanalysis #marketresearch #competitiveintelligence #biogen #sagetherapeutics #leadership #lifesciences #pharmaceuticalindustry
To view or add a comment, sign in
-
How does difficult-to-treat depression (DTD) affect patients in Europe who later undergo adjunctive VNS Therapy for DTD? Our most recent paper provides some interesting new perspectives https://lnkd.in/eUgTVqte
Baseline characteristics of a European patient population with difficult-to-treat depression (RESTORE-LIFE) treated with adjunctive vagus nerve stimulation
sciencedirect.com
To view or add a comment, sign in
-
MD Spec Anesthesia Intensive Care, Pain Therapy, Palliative Care, PhD Neuroscience, Psychology, Psychiatry, Coordinator Consciousness researches at Neurobioethics GdN, at UNESCO Chair Bioethics and Human Rights, UPRA
Anxiety and psychosomatic symptoms in palliative care: from neuro-psychobiological response to stress, to symptoms’ management with clinical hypnosis and meditative states. by Anirudh Kumar Satsangi1, Maria Paola Brugnoli2 indexed in PubMed https://lnkd.in/dfT8XK2i
Anxiety and psychosomatic symptoms in palliative care: from neuro-psychobiological response to stress, to symptoms’ management with clinical hypnosis and meditative states
apm.amegroups.org
To view or add a comment, sign in
-
MD Spec Anesthesia Intensive Care, Pain Therapy, Palliative Care, PhD Neuroscience, Psychology, Psychiatry, Coordinator Consciousness researches at Neurobioethics GdN, at UNESCO Chair Bioethics and Human Rights, UPRA
Anxiety and psychosomatic symptoms in palliative care: from neuro-psychobiological response to stress, to symptoms' management with clinical hypnosis and meditative states.Satsangi AK, Brugnoli MP. Ann Palliat Med. 2018 Jan;7(1):75-111. doi: 10.21037/apm.2017.07.01. Epub 2017 Aug 9. PMID: 28866901 Free article. Review. https://lnkd.in/eE6eNwpQ
Anxiety and psychosomatic symptoms in palliative care: from neuro-psychobiological response to stress, to symptoms' management with clinical hypnosis and meditative states - PubMed
pubmed.ncbi.nlm.nih.gov
To view or add a comment, sign in
-
😛 One single dose of LSD seems to do wonders for anxiety and depression, according to a fresh study. The American company Mind Medicine's anxiety-treating MM120 has been granted designation ahead of Phase 3 trials after showing promising results in their Phase 2 trial. Twelve weeks after receiving a dose in a Phase 2 trial, 48% of patients were in remission and 65% saw significantly improved symptoms. "The clinical improvement for many patients was more than double what we see with today's standard of care..." says Dr. Daniel Karlin, MindMed's Chief Medical Officer, and assistant professor of psychiatry at Tufts University School of Medicine. While it was not the study’s primary purpose, results did show that MM120 also improved signs of depression. The American Food and Drug Administration (FDA) has given the LSD formulation breakthrough therapy status, which hastens the development and approval process. Two other formulas have also received FDA breakthrough therapy status: psilocybin for treatment-resistant depression, and MDMA (commonly known as ecstasy or molly) for post-traumatic stress disorder or PTSD. Article in the comment section. #mentalhealth #healthtech #lsd
To view or add a comment, sign in
-